{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:35:05Z","timestamp":1787243705889,"version":"build-2736575974"},"reference-count":64,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>When imatinib, the first tyrosine kinase inhibitor (TKI) developed for use in chronic myelogenous leukemia (CML), was approved in 2001, the treatment of this disease was forever changed. Significant reductions in the molecular burden of disease were seen with the first-generation TKI imatinib and, with the addition of dasatinib (2006), nilotinib (2007), bosutinib (2012), and ponatinib (2013), deeper and more rapid reductions were noted. Physicians could begin to tailor TKI therapy to individual patients, and patients who did not respond to or could not tolerate first-line therapy now had options. Importantly, the number of patients who developed accelerated or blast phase disease decreased dramatically. Research in CML continues to evolve; by presenting illustrative cases, this article reviews some of the newer aspects of clinical care in this disease. Updated information regarding bosutinib and asciminib, the latter currently in clinical trials, will be presented; bosutinib is of particular interest as the drug\u2019s transit through the United States Food and Drug Administration highlights the question of what is considered optimal response to TKI therapy. The challenge of understanding the cardiac safety data of ponatinib and the unique dosing schedule based on individual response will be discussed. Lastly, two cases will focus on features of TKI treatment that, remarkably, have become part of the treatment algorithm: family planning for women with CML and stopping therapy after meeting a specific treatment milestone.<\/jats:p>","DOI":"10.1182\/blood.2021011722","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T15:19:17Z","timestamp":1631805557000},"page":"3138-3147","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["How I treat chronic-phase chronic myelogenous leukemia"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3973-0230","authenticated-orcid":false,"given":"Ellin","family":"Berman","sequence":"first","affiliation":[{"name":"Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2022052615231276100_B1","first-page":"1497","article-title":"A minute chromosome in chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1950","journal-title":"Science."},{"issue":"5405","key":"2022052615231276100_B2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature."},{"issue":"5940","key":"2022052615231276100_B3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/306239a0","article-title":"Localization of the c-abl oncogene to a translocation breakpoint in chronic myelocytic leukaemia","volume":"306","author":"Heisterkamp","year":"1983","journal-title":"Nature."},{"issue":"5","key":"2022052615231276100_B4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med."},{"issue":"7","key":"2022052615231276100_B5","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood-2012-03-378919","article-title":"How I treat newly diagnosed chronic phase CML","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood."},{"issue":"23","key":"2022052615231276100_B6","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res."},{"issue":"28","key":"2022052615231276100_B7","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022052615231276100_B8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022052615231276100_B9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell."},{"key":"2022052615231276100_B10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-133922","article-title":"Efficacy and safety of ponatinib in patients with chronic-phase chronic myeloid leukemia who failed one or more second generation (2G) tyrosine kinase inhibitors (TKIs): analysis based on PACE and OPTIC","volume":"136","author":"Kantarjian","year":"2020","journal-title":"Blood."},{"issue":"7647","key":"2022052615231276100_B11","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature."},{"issue":"24","key":"2022052615231276100_B12","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor therapy failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med."},{"issue":"10","key":"2022052615231276100_B13","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia."},{"issue":"10","key":"2022052615231276100_B14","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3324\/haematol.2012.080234","article-title":"The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis","volume":"98","author":"Nicolini","year":"2013","journal-title":"Haematologica."},{"issue":"22","key":"2022052615231276100_B15","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med."},{"issue":"19","key":"2022052615231276100_B16","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med."},{"issue":"24","key":"2022052615231276100_B17","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med."},{"issue":"24","key":"2022052615231276100_B18","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med."},{"key":"2022052615231276100_B19"},{"issue":"4","key":"2022052615231276100_B20","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/CIR.0000000000000156","article-title":"2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards)","volume":"132","author":"Hicks","year":"2015","journal-title":"Circulation."},{"key":"2022052615231276100_B21","doi-asserted-by":"crossref","first-page":"7550","DOI":"10.1200\/JCO.2020.38.15_suppl.7550","article-title":"Retrospective independent review of arterial occlusive events in the ponatinib phase 2 PACE trial (NCT01207440) in patients with Philadelphia chromosome positive leukemia","volume":"38","author":"Januzzi","year":"2020","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022052615231276100_B22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol."},{"issue":"8","key":"2022052615231276100_B23","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3563","article-title":"Role of ABL family kinases in cancer: from leukaemia to solid tumours","volume":"13","author":"Greuber","year":"2013","journal-title":"Nat Rev Cancer."},{"issue":"4","key":"2022052615231276100_B24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1582-4934.2005.tb00379.x","article-title":"Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF)","volume":"9","author":"Byrne","year":"2005","journal-title":"J Cell Mol Med."},{"issue":"1","key":"2022052615231276100_B25","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/157016110790226660","article-title":"Thromboembolic events in patients treated with anti-angiogenic drugs","volume":"8","author":"Ferroni","year":"2010","journal-title":"Curr Vasc Pharmacol."},{"issue":"1","key":"2022052615231276100_B26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1538-7836.2008.03212.x","article-title":"Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice","volume":"7","author":"Meyer","year":"2009","journal-title":"J Thromb Haemost."},{"issue":"9","key":"2022052615231276100_B27","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00417-012-2055-z","article-title":"Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye","volume":"250","author":"Schraermeyer","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"issue":"7487","key":"2022052615231276100_B28","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nature12883","article-title":"Leukaemogenesis induced by an activating \u03b2-catenin mutation in osteoblasts","volume":"506","author":"Kode","year":"2014","journal-title":"Nature."},{"issue":"7","key":"2022052615231276100_B29","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.leukres.2013.02.005","article-title":"Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors","volume":"37","author":"Berman","year":"2013","journal-title":"Leuk Res."},{"issue":"6","key":"2022052615231276100_B30","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia."},{"issue":"10","key":"2022052615231276100_B31","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1634\/theoncologist.2011-0137","article-title":"Will imatinib compromise reproductive capacity?","volume":"16","author":"Zamah","year":"2011","journal-title":"Oncologist."},{"issue":"12","key":"2022052615231276100_B32","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.24186","article-title":"The impact of dasatinib on pregnancy outcomes","volume":"90","author":"Cortes","year":"2015","journal-title":"Am J Hematol."},{"key":"2022052615231276100_B33","article-title":"Sprycel (dasatinib) prescribing information","author":"Bristol-Myers Squibb Company"},{"key":"2022052615231276100_B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040620720966120","article-title":"Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence and recommendations","volume":"11","author":"Abruzzese","year":"2020","journal-title":"Ther Adv Hematol."},{"issue":"3","key":"2022052615231276100_B35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ajmg.10781","article-title":"Teratogen-induced limb defects","volume":"112","author":"Holmes","year":"2002","journal-title":"Am J Med Genet."},{"issue":"12","key":"2022052615231276100_B36","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood."},{"key":"2022052615231276100_B37","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1007\/s00277-015-2317-z","article-title":"Managing pregnancy in chronic myeloid leukaemia","volume":"94","author":"Palani","year":"2015","journal-title":"Ann Hematol."},{"issue":"12","key":"2022052615231276100_B38","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1200\/JCO.2017.77.2574","article-title":"Chronic myelogenous leukemia: pregnancy in the era of stopping tyrosine kinase inhibitor therapy [published correction appears in J Clin Oncol. 2018;36(15):1541]","volume":"36","author":"Berman","year":"2018","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022052615231276100_B39","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1515\/JPM.2000.047","article-title":"Administration of interferon-\u03b1 during pregnancy: effects on fetus","volume":"28","author":"Hiratsuka","year":"2000","journal-title":"J Perinat Med."},{"issue":"147","key":"2022052615231276100_B40","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00432-020-03430-4","article-title":"Interferon alpha for essential thrombocytehmai during 34 high risk pregnancies: outcome and safety","volume":"2121","author":"Schrickel","year":"2021","journal-title":"J Cancer Res Clin Oncol."},{"issue":"10","key":"2022052615231276100_B41","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic Myeloid Leukemia, Version 2.2020, NCCN practice guidelines in oncology","volume":"18","author":"Deininger","year":"2020","journal-title":"J Natl Compr Canc Netw."},{"issue":"28","key":"2022052615231276100_B42","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1200\/JCO.2008.20.3869","article-title":"High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses","volume":"27","author":"Cortes","year":"2009","journal-title":"J Clin Oncol."},{"issue":"18","key":"2022052615231276100_B43","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1056\/NEJMcp1307341","article-title":"Clinical practice. Cryopreservation of oocytes","volume":"373","author":"Schattman","year":"2015","journal-title":"N Engl J Med."},{"issue":"4","key":"2022052615231276100_B44","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia."},{"issue":"32","key":"2022052615231276100_B45","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.2011.36.0693","article-title":"Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?","volume":"29","author":"Jabbour","year":"2011","journal-title":"J Clin Oncol."},{"issue":"12","key":"2022052615231276100_B46","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood."},{"key":"2022052615231276100_B47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-139677","article-title":"Asciminib, a first-in class STAMP inhibitor, provides durable molecular response in chronic myeloid leukemia (CNL) harboring the T215I mutation: primary efficacy and safety results from a phase 1 trial","volume":"136","author":"Cortes","year":"2020","journal-title":"Blood."},{"key":"2022052615231276100_B48","doi-asserted-by":"crossref","first-page":"LBA-4","DOI":"10.1182\/blood-2020-143816","article-title":"Efficacy and safety results from ASCEMBL, a multicenter, open label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase previously treated with \u2265 2 tyrosine kinase inhibitors","volume":"136","author":"Hochhaus","year":"2020","journal-title":"Blood."},{"issue":"11","key":"2022052615231276100_B49","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"issue":"12","key":"2022052615231276100_B50","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1038\/s41375-018-0264-0","article-title":"Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells","volume":"32","author":"Ross","year":"2018","journal-title":"Leukemia."},{"issue":"15","key":"2022052615231276100_B51","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1016\/j.ejca.2013.06.018","article-title":"Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)","volume":"49","author":"Thielen","year":"2013","journal-title":"Eur J Cancer."},{"key":"2022052615231276100_B52","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol."},{"issue":"10","key":"2022052615231276100_B53","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","article-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study","volume":"90","author":"Mori","year":"2015","journal-title":"Am J Hematol."},{"issue":"6","key":"2022052615231276100_B54","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study","volume":"101","author":"Lee","year":"2016","journal-title":"Haematologica."},{"issue":"7","key":"2022052615231276100_B55","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood."},{"issue":"3","key":"2022052615231276100_B56","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","article-title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study","volume":"61","author":"Shah","year":"2020","journal-title":"Leuk Lymphoma."},{"issue":"3","key":"2022052615231276100_B57","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","article-title":"Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial","volume":"7","author":"Kimura","year":"2020","journal-title":"Lancet Haematol."},{"key":"2022052615231276100_B58","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","article-title":"Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment","volume":"18","author":"Okada","year":"2018","journal-title":"Clin Lymph Myeloma Leuk."},{"issue":"6","key":"2022052615231276100_B59","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"issue":"5","key":"2022052615231276100_B60","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","article-title":"Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study","volume":"144","author":"Ross","year":"2018","journal-title":"J Cancer Res Clin Oncol."},{"issue":"7","key":"2022052615231276100_B61","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment free remission after second line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single- group phase 2, open-label study","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann Intern Med."},{"issue":"4","key":"2022052615231276100_B62","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood."},{"issue":"3","key":"2022052615231276100_B63","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood."},{"issue":"3","key":"2022052615231276100_B64","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bjh.16083","article-title":"Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome","volume":"187","author":"Berger","year":"2019","journal-title":"Br J Haematol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/21\/3138\/1898550\/bloodbld2021011722.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/21\/3138\/1898550\/bloodbld2021011722.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T11:24:31Z","timestamp":1653564271000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/21\/3138\/476939\/How-I-treat-chronic-phase-chronic-myelogenous"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":64,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2022,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021011722","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]}}}